SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : EntreMed (ENMD) -- Ignore unavailable to you. Want to Upgrade?


To: Jon Koplik who wrote (1378)11/12/1998 2:19:00 PM
From: Mr. Miller  Read Replies (1) | Respond to of 2135
 
Certainly Wallstreet overhyped this company earlier this year. I called Waterhouse Securities today, and they said they have no shares to short. With this in mind, and the worst over for right this moment, and the fact that the CEO is coming on and has issued this press release, I think we get a small bounce back to $30. If noone else can short, I think the stock does not go down further since noone will sell till they hear the CEO out. I think the shorts are now covering, moving the price up slowly, while everyone else waits to see what the CEO says. If it is anything good, the stock will rebound smartly from buying and a squeeze. Shorts, I would cover. No sense in being greedy. Good chance for short term "longs" to make a few bucks off the shorts.

Miller



To: Jon Koplik who wrote (1378)11/12/1998 2:25:00 PM
From: Mr. Miller  Read Replies (1) | Respond to of 2135
 
Kernen about to talk about ENMD on CNBC.




To: Jon Koplik who wrote (1378)11/12/1998 2:36:00 PM
From: Henry Niman  Read Replies (2) | Respond to of 2135
 
I think that the background behind the anti-angiogenesis story is a good one for any investor in biotechs, so I have started an Anti-Angiogenesis table on the New Therapeutics page at biocognizance.com